# LL37 – 5mg/vial (Research Use Only)

### Overview

LL-37 is the sole member of the cathelicidin family of host-defense peptides expressed in humans, cleaved from the C-terminus of the precursor protein hCAP18 (human cationic antimicrobial protein 18). As the principal human cathelicidin, LL-37 has generated extensive published research across antimicrobial pharmacology, immunomodulation, wound healing biology, angiogenesis, and cancer biology. Its dual roles as a direct antimicrobial agent and an immunomodulatory signaling molecule — acting on FPR2/FPRL1, P2X7, and EGF receptor among other targets — make it one of the most mechanistically versatile research peptides in innate immunity.

### What It Is

LL-37 is an amphipathic alpha-helical 37-amino acid peptide with the N-terminal sequence LL (Leu-Leu), cleaved from the C-terminal region of hCAP18 by serine protease (proteinase 3) processing. Molecular formula: C₂₀₅H₃₄₀N₆₀O₅₃S (approximate), MW approximately 4,493 Da, CAS number 154947-66-7. Its amphipathic alpha-helical structure enables membrane disruption of bacterial, fungal, and viral lipid membranes while also engaging eukaryotic cell surface receptors including FPR2/FPRL1, EGFR, and P2X7 purinergic receptor.

### Key Research Applications

- Antimicrobial activity research — bacterial membrane disruption and MIC studies
- Host defense peptide biology and innate immunity research
- FPR2/FPRL1 and EGFR receptor activation and downstream signaling studies
- Wound healing research — epithelial cell migration, proliferation, and angiogenesis studies
- Anti-biofilm activity and anti-bacterial resistance mechanism research
- Immunomodulatory pathway research — macrophage, dendritic cell, and neutrophil activation
- Cancer biology — dual pro-apoptotic and pro-survival LL-37 effect research
- Antiviral mechanism studies — enveloped virus membrane interaction research

### Technical Specifications

| Amino Acids | 37 (N-terminal Leu-Leu sequence) |
| --- | --- |
| Molecular Weight | ~4,493 Da |
| CAS Number | 154947-66-7 |
| Origin | Human cathelicidin CAMP gene product (hCAP18 C-terminal fragment) |
| Mechanism | Antimicrobial membrane disruptor; FPR2/FPRL1 and EGFR agonist |
| Purity | ≥98% (supplier specification) |
| Form | Lyophilized powder |
| Vial Size | 5mg |
| Storage | −4 °F long-term; avoid repeated freeze-thaw cycles |

**FOR RESEARCH USE ONLY.** Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

---

Source: https://portaltowellness.net/shop/ll37/
Research use only. Terms: https://portaltowellness.net/research-use-only/